Market Place
Sourcing Support
All News #Library
Biotech
Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
02 Apr 2026 //
GLOBENEWSWIRE
Equillium To Participate In The 38th Annual Roth Conference
18 Mar 2026 //
GLOBENEWSWIRE
Equillium To Join Leerink Partners Global Healthcare Conference
25 Feb 2026 //
GLOBENEWSWIRE
Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
02 Feb 2026 //
GLOBENEWSWIRE
Equillium To Participate In Upcoming Investor Conferences
20 Nov 2025 //
GLOBENEWSWIRE
Equillium To Participate In Upcoming Investor Conferences
04 Nov 2025 //
GLOBENEWSWIRE
Equillium Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
03 Nov 2025 //
GLOBENEWSWIRE
Equillium Hosts Ulcerative Colitis KOL Event On Nov 5, 2025
22 Oct 2025 //
GLOBENEWSWIRE
Equillium Announces Leadership And Corporate Updates
06 Oct 2025 //
GLOBENEWSWIRE
Equillium to Present at Cantor Global Healthcare Conference 2025
29 Aug 2025 //
BUSINESSWIRE
Equillium Announces Poster Presentations on EQ504 at AAI Meeting
06 May 2025 //
BUSINESSWIRE
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program
01 May 2025 //
BUSINESSWIRE
Equillium Reports 2024 Financial Results and Corporate Highlights
27 Mar 2025 //
BUSINESSWIRE
Equillium announces Phase 3 study results for Itolizumab in GVHD
27 Mar 2025 //
BUSINESSWIRE
Equillium Reports Positive Phase 2 Data for Itolizumab in UC
06 Feb 2025 //
BUSINESSWIRE
Equillium to Present at the Stifel Healthcare Conference
13 Nov 2024 //
BUSINESSWIRE
Equillium Reports Q3 2024 Financial Results & Corporate Updates
13 Nov 2024 //
BUSINESSWIRE
Equillium Announces Poster Presentation at SITC Conference
12 Nov 2024 //
BUSINESSWIRE
Equillium Maintains Itolizumab Rights After Ono Partnership
31 Oct 2024 //
BUSINESSWIRE
Equillium To Present At Stifel Virtual Inflammation Summit
10 Sep 2024 //
BUSINESSWIRE
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Sep 2024 //
BUSINESSWIRE
Equillium Reports Q2 2024 Results And Corporate Highlights
08 Aug 2024 //
BUSINESSWIRE
Equillium Announces Positive Analysis from Phase 3 EQUATOR Study of Itolizumab
06 Aug 2024 //
BUSINESSWIRE
Equillium Announces Interim EQUATOR GVHD Enrollment Achieved
14 May 2024 //
BUSINESSWIRE
Equillium Announces Positive Data from the Ph 1b EQUALISE study
01 Apr 2024 //
BUSINESSWIRE
Equillium Announces Data from Deliverable Multi-Cytokine Inhibitor
16 Oct 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.